Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of dapirolizumab pegol in systemic lupus erythematosus
NL-OMON60019Phase 3Not yet recruiting
- Sponsor
- UCB
- Start
- Sep 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dapirolizumab pegol in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious treatment-emergent adverse events and 1 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON60019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60019.